6820-79-7

Upstream product

• 14510-37-3 3-acetoxy-2-phenyl-propionyl chloride 
• 108-24-7 acetic anhydride 
• 75-36-5 acetyl chloride 
• 51-34-3 scopolamine 
• 114-49-8 hyoscine hydrobromide 

Downstream Products

• 26516-78-9 (S)-3-acetoxy-2-phenyl-propionic acid 9-cyano-(1rN,2tH,4tH,5cN)-3-oxa-9-aza-tricyclo[3.3.1.0^2,4]non-7t-yl ester 
• 25645-57-2 (-)-N-Chlorformyl-O-acetylnorscopolamin 
• 492-38-6 2-phenylacrylic acid 
• 64-19-7 acetic acid 
• 487-27-4 (+/-)-scopoline 
• 64307-65-9 (S)-3-acetoxy-2-phenyl-propionic acid 9-(5-dimethylamino-naphthalene-1-sulfonyl)-(1rN,2tH,4tH,5cN)-3-oxa-9-aza-tricyclo[3.3.1.0^2,4]non-7t-yl ester 
• 25650-58-2 (-)-Formylnorscopollamin 
• 4684-28-0 Norscopolamine 
• 26352-27-2 (-)-Azoniaspiro-(norscopolamin-8,1'-pyrrolidin)-bromid 

Relevant academic research and scientific papers

Synthesis and evaluation of enzyme inhibitory potential of some derivatives of scopolamine

This study was designed to synthesize and evaluate derivatives of scopolamine (1) as acetylcholine esterase and protease inhibitors. Scopolamine (1) was extracted from the aerial parts of Datura innoxia through bioassay guided fractionation. Five different derivatives of scopolamine (1) were synthesized, and identified through spectroscopic studies. Their acetylcholine esterase (AChE) and trypsin inhibitory potentials were determined through standard protocols and evaluated from the perspective of structure-activity relationship. The synthesized scopolamine derivatives (2-6) showed remarkable AChE inhibitory activity, except for scopoline (6). The results showed higher enzyme inhibition potential of the synthesized compounds (2-5) as compared to scopolamine (1). Maximum inhibition was exhibited by scopolamine N -oxide (89.9 ± 1.2%, IC50 = 37.4 ± 1.1 μM)), followed by scopolamine sulfonic acid (70.3 ± 0.8%, IC50 = 46.9 ± 1.0 μM) and O-methyl scopolamine (66.1 ± 1.2%, IC50 = 94.7 ± 0.8 μM). All derivatives showed moderate activity against trypsin; maximum activity was exhibited by 6 (54.0 ± 1.4%) with IC50 = 621.2 ± 3.7 μM.

The synthesis of anticholinergically active N-alkylnorscopolamines and their quaternary salts with particular consideration of the bronchospasmolytic compound (-)-N-ethylnorscopolamine methobromide (Ba 253 BR)

The synthesis of anticholinergic N-alkylnorscopolamines and their quaternary salts, especially the synthesis of (-)-N-ethylnorscopolamine methobromide (Ba 253 BR), is reported. (-)-N-Ethylnorscopolamine methobromide differs from the stereoisomeric (-)-N-ethylscopolammonium bromide not only by its physico-chemical, but also by its pharmacological properties. (-)-N-Ethylnorscopolamine methobromide represents an anticholinergic bronchodilator with long duration of action.